Core Viewpoint - Hutchison China MediTech Limited (00013.HK) announced a conference scheduled for October 31, 2025, in Shanghai, China, to share its latest research and development progress, which will be live-streamed online [1] Group 1 - The conference will feature Dr. Shi Mingbo, Executive Vice President, Head of R&D, and Chief Medical Officer, who will discuss the company's R&D strategy and vision [1] - The presentation will include an overview of the company's Antibody-Drug Conjugate (ADC) platform and highlight its first candidate drug, HMPL-A251 [1] - Updates on the later-stage R&D pipeline will also be shared during the event [1]

Core Insights - HUTCHMED will host a Research & Development update on October 31, 2025, in Shanghai and via webcast [1][2] Group 1: Event Details - The event will feature Dr. Michael Shi, who will discuss the company's R&D strategy, including the Antibody Targeted Therapy Conjugates platform and updates on late-stage pipeline development [2] - The in-person event will take place from 3:00 p.m. to 5:00 p.m. HKT and will be conducted in Chinese, with a live English webcast at 8:00 p.m. HKT [3] - Both webcasts will be available live on the company website, with a replay accessible shortly after the event [4] Group 2: Company Overview - HUTCHMED is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases [5] - The company has successfully marketed its first three medicines in China, with the first also approved globally, including in the US, Europe, and Japan [5]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不 對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 HUTCHMED (China) Limited 和黃醫藥（中國）有限公司 （於開曼群島註冊成立的有限公司） （股份代號：13） 自願性公告 會議通知：和黃醫藥將於2025年10月31日介紹最新研發進展 — 和黃醫藥將於10月31日（星期五）舉行線下和線上會議 — 和黃醫藥（中國）有限公司（簡稱「和黃醫藥」或「HUTCHMED」）今日宣佈將於2025年10月31日（星期五）在 中國上海舉辦會議分享最新研發進展，並將通過網絡同步直播。 活動期間，和黃醫藥執行副總裁、研發負責人兼首席醫學官石明博士將分享公司的研發策略和願景，包括概述公司 抗體靶向偶聯藥物（ATTC）平台並重點介紹其首個候選藥物HMPL-A251，以及後期研發管綫的最新進展。 線下會議將於中國香港時間下午3時至5時於上海舉行，會議語言為中文（普通話），並將於網絡同步直播。現場活 動僅限受邀人士參與。 此外，英文場次的網絡會議將於10月31日（星 ...

Major Events - Yunzhisheng (09678) is actively exploring new sustainable business models and project opportunities [1] - Junshi Biosciences (01877) achieved the primary endpoint in the Phase III clinical study of anti-IL-17A monoclonal antibody for moderate to severe plaque psoriasis [1] - Hutchison China MediTech (00013) will present the latest data on several self-developed compounds at the 2025 World Lung Cancer Congress and the 2025 Annual Meeting of the Chinese Society of Clinical Oncology [1] - InnoCare Pharma-B (09606) reached the primary endpoint in the Phase III clinical trial of DB-1303/BNT323 for HER2-positive unresectable or metastatic breast cancer patients [1] - Heng Rui Medicine (01276) plans to license its Class 1 innovative drug HRS-1893 to Braveheart Bio to expand into overseas markets [1] Financial Data - Aoyuan Group (01813) reported a pre-sale amount of 611 million yuan in August, a year-on-year decrease of 13.9% [1] - GAC Group (02238) sold 135,700 vehicles in August, a year-on-year decline of 8.43% [1] - Zhongliang Holdings (02772) recorded a cumulative contract sales amount of approximately 8.29 billion yuan in the first eight months, a year-on-year decrease of 32.71% [1] - Xiehe New Energy (00182) reported a total equity power generation of 507.64 GWh in August, a year-on-year increase of 6.07% [1] - Zhengrong Real Estate (06158) had a cumulative contract sales amount of approximately 2.99 billion yuan in the first eight months, a year-on-year decrease of 30.8% [1]

Core Viewpoint - Hutchison China MediTech Limited (和黄医药) is set to present updated data on its self-developed compounds at two major conferences in September 2025, highlighting its ongoing research in lung cancer treatment [1] Group 1: Upcoming Conferences - The company will present at the 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain from September 6 to 9 [1] - The company will also present at the 2025 Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) in Jinan, China from September 10 to 14 [1] Group 2: Research Focus - The latest analysis results of the SACHI study, SAVANNAH study, and a Phase IIIb confirmatory study of Savolitinib (赛沃替尼) for non-small cell lung cancer will be disclosed at the WCLC [1] - Savolitinib is described as a potent and highly selective oral MET tyrosine kinase inhibitor (TKI), co-developed by AstraZeneca and Hutchison China MediTech, with commercialization handled by AstraZeneca [1]

Core Viewpoint - HCM's stock rose over 6% to $15.76 following the announcement of upcoming data presentations at major oncology conferences in 2025 [1] Group 1: Upcoming Conferences - HCM will present updated research data on its proprietary compounds at the 2025 World Lung Cancer Conference (WCLC) in Barcelona from September 6 to 9, and at the 2025 Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) in Jinan, China, from September 10 to 14 [1] Group 2: Key Research Studies - The latest analysis results of the SACHI and SAVANNAH studies, which evaluate the efficacy of Savolitinib for treating non-small cell lung cancer, will be presented at the WCLC [1] - Data from the first human Phase I clinical trial of HMPL-653, a novel selective and potent CSF-1R inhibitor, in patients with tenosynovial giant cell tumors will be unveiled at the CSCO meeting [1]

Core Viewpoint - HCM's stock price increased by over 6% to $15.76 following the announcement of upcoming data presentations at major oncology conferences in 2025 [1] Group 1: Upcoming Events - HCM will present updated data on its proprietary compounds at the 2025 World Lung Cancer Conference (WCLC) in Barcelona from September 6 to 9, and at the 2025 Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) in Jinan, China, from September 10 to 14 [1] Group 2: Research Highlights - The latest analysis results of the SACHI and SAVANNAH studies, as well as a Phase IIIb confirmatory study of Savolitinib for non-small cell lung cancer, will be presented at the WCLC [1] - Data from the first human Phase I clinical trial of HMPL-653, a novel selective and potent CSF-1R inhibitor, in patients with tenosynovial giant cell tumors will be unveiled at the CSCO meeting [1]

Group 1: Market Overview - The Hang Seng Index rose by 0.62%, while the Hang Seng Tech Index increased by 0.82%, with a total turnover of HKD 124.6 billion in the morning session [1] - The Hang Seng Biotechnology Index surged by 3.1%, driven by optimism in the innovative drug sector ahead of the 2025 World Lung Cancer Conference, indicating potential for valuation recovery [1] Group 2: Company Performances - Three-Six Pharmaceutical (01530) saw a significant increase of 9.6% [1] - Hengrui Medicine-B (02142) rose by 5.82% [1] - Hutchison China MediTech (00013) increased by 6% [1] - United Laboratories (03933) gained 5% [1] - WuXi Biologics (02269) rose by 4.17% [1] Group 3: Other Notable Stocks - Chow Tai Fook (06168) surged over 13% as the gold consumption market enters a peak season, with expectations of inclusion in the Hong Kong Stock Connect [2] - FunPlus (09890) increased by over 5% after completing a name change and upgrading its overseas brand integration, with a higher proportion of overseas revenue in the first half [2] - Lehua Entertainment (02306) rose by 16%, with a nearly 90% year-on-year increase in interim profit attributable to shareholders, expanding monetization channels for its trendy IP [3] - UBTECH Robotics (09880) increased by 3%, with humanoid robot orders reaching CNY 400 million and securing a USD 1 billion strategic investment from a Middle Eastern fund [4] - Mobi Development (01860) surged over 12%, hitting a historical high with a cumulative increase of over 110% this year [5] - Goldwind Technology (02208) rose over 10%, reaching a new high as the wind power sector experiences accelerated growth, leading the industry in gross margin improvement [5] - Zhongshen Jianye (02503) experienced a significant drop, falling over 74% to a historical low, with a loss of CNY 11.81 million in the first half [5]

Group 1 - The core viewpoint is that the innovative drug sector is experiencing a significant upward trend, with multiple companies showing substantial stock price increases ahead of the 2025 World Lung Cancer Conference [1] - Notable stock price increases include: 9.55% for 3SBio, 6.25% for Hengrui Medicine, and 5.16% for WuXi Biologics, indicating strong market interest [1] - The upcoming conference in Barcelona is expected to provide new development opportunities and market attention for innovative drug companies through the release of significant new products [1] Group 2 - In the first seven months of the year, China's innovative drug companies have seen a normalization in business development (BD) overseas, with license out amounts nearing $80 billion, a year-on-year increase of over 160% [2] - Analysts suggest that the essence of China's innovative drug overseas expansion is to replace certain ecological niches of foreign biotech companies, potentially leading to new breakthroughs in the global innovative drug industry [2] - The deep participation of Chinese innovative drugs in the global supply chain is expected to benefit significantly from the global innovation cycle [2]

Core Viewpoint - Hutchison China MediTech Limited (和黄医药) shares rose over 5%, currently at 24.68 HKD with a trading volume of 112 million HKD, following the announcement of upcoming data presentations at major oncology conferences in 2025 [1] Group 1: Upcoming Events - The company will present updated research data on its proprietary compounds at the 2025 World Lung Cancer Conference (WCLC) in Barcelona from September 6 to 9, and at the 2025 Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) in Jinan, China from September 10 to 14 [1] Group 2: Research Highlights - The latest analysis results of the SACHI and SAVANNAH studies, as well as a Phase IIIb confirmatory study of Savolitinib (赛沃替尼), will be presented at the WCLC. Savolitinib is a potent and selective oral MET tyrosine kinase inhibitor co-developed by AstraZeneca and Hutchison China MediTech [1] - The first human Phase I clinical trial data of HMPL-653, a novel, selective, and potent CSF-1R inhibitor, in patients with tenosynovial giant cell tumors will be unveiled at the CSCO annual meeting [1]